GET DAILY SIGNALSPetMed Express (PETS) Earnings Preview: Watching for Signs of Stabilization in Q2
Key Takeaways
- PetMed Express (NASDAQ: PETS), which operates as PetMeds, reports results for its second quarter of fiscal 2027 — the three months ended September 30, 2026 — after the market close on Tuesday, November 10, 2026.
- Wall Street consensus projects a net loss of roughly $0.11 per share, with revenue estimated near $62 million, according to MarketBeat consensus data.
- The report is the first quarterly update under new Chief Executive Officer Jeff Willard, who took the role effective September 28, 2026, succeeding interim CEO Leslie Campbell.
- Investors will focus on whether prescription medication sales are stabilizing and whether new business-to-business (B2B) partnerships, including the Rural King agreement, are beginning to lift revenue.
- The prior quarter (Q1 fiscal 2027) delivered net sales of $41 million, down 19.9% year over year, though losses narrowed as cost controls took hold.
- For additional context on the ticker, explore PetMed Express' Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- You can also explore Trending AI Robots to see AI-driven trading strategies currently gaining attention in the market.
Earnings Context and Why It Matters
PetMed Express is a direct-to-consumer online pet pharmacy that is emerging from a difficult "reset" fiscal year. In fiscal 2026, revenue fell 21.1% to $179 million, and a $26.7 million non-cash goodwill impairment helped push the full-year net loss to $57.3 million. Management spent the year cutting costs, upgrading technology, and repositioning the business around retention and partner-led growth. This report will show whether those efforts are translating into slowing sales declines and narrower losses, and whether the company's move into B2B pharmacy fulfillment can begin to offset persistent weakness in its core prescription medication segment. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Earnings Expectations
For the second quarter of fiscal 2027, analyst consensus calls for a net loss of approximately $0.11 per share, with revenue estimated near $62 million, according to MarketBeat. That revenue figure implies a meaningful sequential step-up from the $41 million reported in the first quarter of fiscal 2027, reflecting the potential contribution of new B2B arrangements rather than a rebound in the legacy direct-to-consumer business alone.
In the most recent quarter, PetMed Express posted net sales of $41 million, a 19.9% year-over-year decline, though the net loss narrowed as cost-optimization efforts took hold. Management has previously guided to roughly $6.1 million in annualized savings from exiting underperforming vendor relationships. Key metrics investors will watch include prescription medication sales trends, auto-ship signups, gross margin, and selling, general, and administrative expense levels.
Market Reaction and Investor Sentiment
Sentiment heading into the print remains cautious. PetMed Express shares have traded in a wide 52-week range of roughly $1.15 to $4.10 and have come under sustained pressure, with Morgan Stanley recently lowering its price target to $1.40 from $2.15 while maintaining an Underweight rating. The stock's depressed valuation reflects lingering concerns about the pace of the turnaround and the competitive pet-pharmacy landscape.
Investor attention is also shaped by ongoing acquisition speculation. The company previously received unsolicited proposals, including a $3.00-per-share indication of interest from SilverCape Investments, after the board opted to remain independent rather than pursue earlier offers in the $4.00-to-$4.25 range. A weak quarter could renew focus on strategic alternatives, while evidence of stabilization could support the standalone turnaround thesis.
Forward Outlook and Key Factors to Monitor
Following the report, investors should track whether management reiterates or updates its view on the pace of sales stabilization. The most important signal is the trajectory of prescription medication revenue, which has been the primary driver of recent declines. Sustained improvement in auto-ship signups and customer retention would support the idea that the reset is progressing.
Cost execution remains another key variable. The company has identified approximately $6.1 million in annualized savings from vendor exits, and investors will watch whether those savings flow through to the bottom line without further disruption to sales. The recent completion of a new ERP (enterprise resource planning) system and other technology upgrades should also reduce operational risk over time.
The new CEO transition adds an element of uncertainty. Jeff Willard's strategy and any shift in priorities around B2B partnerships, membership programs, and white-label pharmacy fulfillment will matter for the growth narrative. Meanwhile, the balance sheet provides some cushion, with the company reporting $21.4 million in cash and no debt as of March 31, 2026, supplemented by a planned $37 million sale-leaseback of its headquarters and distribution facilities. Finally, investors should monitor any developments around acquisition interest, which could reintroduce strategic value considerations separate from the operating results. From what I see, tools like Tickeron’s AI Trend Prediction Engine can help track potential shifts in momentum here.
Using AI Tools in My Research Process
In preparing for earnings like this one from PETS, I frequently rely on Tickeron’s AI Screener to filter stocks by industry, patterns, and performance metrics. It allows me to quickly surface comparable names in the pet-care space and evaluate technical setups alongside fundamental trends, making the screening process more efficient than manual methods.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PETS's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for PETS moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 48 similar instances when the indicator left oversold territory. In 33 of the 48 cases the stock moved higher. This puts the odds of a move higher at 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on PETS as a result. In 71 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for PETS just turned positive on October 20, 2026. Looking at past instances where PETS's MACD turned positive, the stock continued to rise in 27 of 46 cases over the following month. The odds of a continued upward trend are 59%.
Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where PETS advanced for three days, in 144 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PETS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
PETS broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PETS entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.151) is normal, around the industry mean (1.378). P/E Ratio (-0.891) is within average values for comparable stocks, (-2.174). Projected Growth (PEG Ratio) (1.270) is also within normal values, averaging (0.947). PETS has a moderately high Dividend Yield (0.984) as compared to the industry average of (0.246). P/S Ratio (0.200) is also within normal values, averaging (2.504).
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. PETS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PETS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 100, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which markets prescription and non-prescription pet medications and other health products for dogs and cats
Industry DrugstoreChains
Advertisement